Imugene (ASX: IMU) chief executive officer and managing director Leslie Chong joins Small Caps to discuss the progress of the company’s phase 1 MAST trial of its novel cancer-killing virus CF33-hNIS – known as VAXINIA.

The oncolytic virus in VAXINIA has been shown to shrink colon, lung, breast, ovarian and pancreatic cancer tumours in preclinical laboratory and animal models. After obtaining promising early results from trials,

Imugene is now increasing its dosage rates for a trial which is combing VAXINIA with pembrolizumab.

Imugene recently reported that 38 patients had been dosed with VAXINIA during the continuing dose escalation phase.

Overall, the study aims to recruit up to 100 patients across approximately 10 trial sites in the United States and Australia.

Articles:
https://smallcaps.com.au/imugene-novel-cancer-treatment-enters-new-phase-mast-trial/
https://smallcaps.com.au/imugene-positive-outcomes-novel-virus-trial-advanced-cancers/

For more information on Imugene:
https://smallcaps.com.au/stocks/asx-imu/

Imugene (ASX: IMU) chief executive officer and managing director Leslie Chong joins Small Caps to discuss the progress of the company’s phase 1 MAST trial of its novel cancer-killing virus CF33-hNIS – known as VAXINIA.
The oncolytic virus in VAXINIA has been shown to shrink colon, lung, breast, ovarian and pancreatic cancer tumours in preclinical laboratory and animal models. After obtaining promising early results from trials,
Imugene is now increasing its dosage rates for a trial which is combing VAXINIA with pembrolizumab.
Imugene recently reported that 38 patients had been dosed with VAXINIA during the continuing dose escalation phase.
Overall, the study aims to recruit up to 100 patients across approximately 10 trial sites in the United States and Australia.
Articles: <a href="https://smallcaps.com.au/imugene-novel-cancer-treatment-enters-new-phase-mast-trial/">https://smallcaps.com.au/imugene-novel-cancer-treatment-enters-new-phase-mast-trial/</a> <a href="https://smallcaps.com.au/imugene-positive-outcomes-novel-virus-trial-advanced-cancers/">https://smallcaps.com.au/imugene-positive-outcomes-novel-virus-trial-advanced-cancers/</a>
For more information on Imugene: <a href="https://smallcaps.com.au/stocks/asx-imu/">https://smallcaps.com.au/stocks/asx-imu/</a>

Small Caps

Small Caps is Australia's #1 site for investor news & information on ASX listed small cap companies. The podcast keeps investors informed by showcasing interviews with directors of ASX listed small cap companies and financial market analysts. For more information visit: https://smallcaps.com.au/.

Small Caps is Australia's #1 site for investor news &amp; information on ASX listed small cap companies. The podcast keeps investors informed by showcasing interviews with directors of ASX listed small cap companies and financial market analysts. For more information visit: https://smallcaps.com.au/.

The Small Caps podcast keeps stock market investors informed with the latest news by interviewing directors of ASX listed small cap companies and financial market analysts.

Small Caps is Australia's #1 site for investor news & information on ASX listed small cap companies.

The podcast keeps investors informed by showcasing interviews with directors of ASX listed small cap companies and financial market analysts.

For more information visit: https://smallcaps.com.au/

Advertisement